|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression |
EXP |
Taurine results in increased expression of ABCB11 protein |
CTD |
PMID:12706339 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Taurine results in increased expression of ABCC2 protein |
CTD |
PMID:12706339 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abl2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
increases expression |
ISO |
Taurine results in increased expression of ABL2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr13:68,673,702...68,770,846
Ensembl chr13:68,673,722...68,839,742
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression multiple interactions |
EXP ISO |
Taurine results in increased expression of ACACA mRNA [NR1H4 protein affects the susceptibility to Taurine] which affects the expression of ACACA mRNA |
CTD |
PMID:26092479 PMID:32062620 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Taurine inhibits the reaction [Malathion results in decreased activity of ACHE protein]; Taurine inhibits the reaction [Manganese results in increased activity of ACHE protein]; Taurine inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein] |
CTD |
PMID:24885898 PMID:27840156 PMID:28987951 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
[Taurine co-treated with Sodium Glutamate] results in increased expression of ACOX1 mRNA |
CTD |
PMID:26092479 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of ACTA2 protein]; Taurine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:30677399 PMID:36310519 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adap2 |
ArfGAP with dual PH domains 2 |
increases expression |
ISO |
Taurine results in increased expression of ADAP2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr10:65,138,006...65,166,147
Ensembl chr10:65,138,020...65,165,604
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of ADGRE1 protein] |
CTD |
PMID:30237538 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases expression |
ISO |
Taurine results in decreased expression of ADORA2A mRNA |
CTD |
PMID:16579726 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
increases expression |
ISO |
Taurine results in increased expression of ADRA1B mRNA |
CTD |
PMID:16579726 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Taurine inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Taurine inhibits the reaction [Glucose results in increased expression of AGT protein] |
CTD |
PMID:12130563 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
decreases expression |
EXP |
Taurine results in decreased expression of AGTR2 protein |
CTD |
PMID:16025228 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of AKT1 protein] Taurine inhibits the reaction [Acrylamide results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:29607694 PMID:30362509 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
EXP |
[Taurine co-treated with monoisoamyl-2,3-dimercaptosuccinate] inhibits the reaction [sodium arsenite results in decreased activity of ALAD protein] |
CTD |
PMID:19794907 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [Alloxan results in increased expression of APAF1 protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of APAF1 protein] |
CTD |
PMID:20830294 PMID:23092809 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
[Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in increased expression of ATG7 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of ATP5PD mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
Taurine inhibits the reaction [Alloxan results in increased expression of BAD protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of BAD protein] |
CTD |
PMID:19429265 PMID:19616567 PMID:20830294 PMID:22138235 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Taurine inhibits the reaction [Acrylamide results in increased expression of BAX protein]; Taurine inhibits the reaction [Alloxan results in increased expression of BAX protein]; Taurine inhibits the reaction [hexabromocyclododecane results in increased expression of BAX protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of BAX mRNA]; Taurine inhibits the reaction [sodium arsenite results in increased expression of BAX protein] |
CTD |
PMID:19616567 PMID:20830294 PMID:22138235 PMID:23092809 PMID:28849447 PMID:29607694 PMID:30101532 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Taurine inhibits the reaction [Acetaminophen results in increased expression of BCL2 protein modified form]; Taurine inhibits the reaction [Acrylamide results in decreased expression of BCL2 protein]; Taurine inhibits the reaction [Alloxan results in decreased expression of BCL2 protein]; Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; Taurine inhibits the reaction [hexabromocyclododecane results in decreased expression of BCL2 protein]; Taurine inhibits the reaction [sodium arsenite results in decreased expression of BCL2 mRNA]; Taurine inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein] |
CTD |
PMID:19429265 PMID:19616567 PMID:20166895 PMID:20830294 PMID:22138235 PMID:23092809 PMID:28849447 PMID:29607694 PMID:30101532 PMID:30551535 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [Acetaminophen results in increased expression of BCL2L1 protein modified form]; Taurine inhibits the reaction [Alloxan results in decreased expression of BCL2L1 protein]; Taurine inhibits the reaction [sodium arsenite results in decreased expression of BCL2L1 protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L1 protein alternative form] |
CTD |
PMID:19616567 PMID:20166895 PMID:20830294 PMID:22138235 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
EXP |
Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein alternative form] |
CTD |
PMID:20830294 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [arsenite results in decreased expression of BDNF mRNA] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF protein] |
CTD |
PMID:23744399 PMID:33368748 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
Taurine results in decreased expression of BID mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases abundance |
ISO |
BMAL1 gene mutant form results in increased abundance of Taurine |
CTD |
PMID:27056296 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
decreases expression |
ISO |
Taurine results in decreased expression of BMPR2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Cap2 |
cyclase associated actin cytoskeleton regulatory protein 2 |
decreases expression increases expression |
ISO |
Taurine results in decreased expression of CAP2 mRNA Taurine results in increased expression of CAP2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr17:18,054,234...18,203,453
Ensembl chr17:18,054,431...18,203,373
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] Taurine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of CASP1 protein] Taurine inhibits the reaction [Arsenic Trioxide results in increased activity of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:30237538 PMID:30660605 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; [Taurine co-treated with Zinc Acetate] inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Taurine inhibits the reaction [Acrylamide results in increased activity of CASP3 protein]; Taurine inhibits the reaction [Alloxan results in increased expression of CASP3 protein modified form]; Taurine inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Taurine inhibits the reaction [hexabromocyclododecane results in increased activity of CASP3 protein]; Taurine inhibits the reaction [Nandrolone Decanoate results in increased expression of CASP3 protein]; Taurine inhibits the reaction [sodium arsenite results in increased activity of and results in increased expression of CASP3 protein]; Taurine inhibits the reaction [sodium arsenite results in increased cleavage of and results in increased activity of CASP3 protein]; Taurine inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; Taurine promotes the reaction [pyrazolanthrone inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]] |
CTD |
PMID:19429265 PMID:19616567 PMID:20830294 PMID:22138235 PMID:23092809 PMID:25542992 PMID:26335259 PMID:28849447 PMID:29607694 PMID:30101532 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Taurine inhibits the reaction [Alloxan results in increased expression of CASP9 protein modified form]; Taurine inhibits the reaction [Alloxan results in increased expression of CASP9 protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of CASP9 protein] |
CTD |
PMID:20830294 PMID:22138235 PMID:23092809 PMID:30101532 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casq1 |
calsequestrin 1 |
increases expression |
EXP |
Taurine results in increased expression of CASQ1 protein |
CTD |
PMID:19423840 |
|
NCBI chr13:84,670,648...84,680,339
Ensembl chr13:84,670,649...84,680,339
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
monoisoamyl-2,3-dimercaptosuccinate promotes the reaction [Taurine inhibits the reaction [sodium arsenite results in increased activity of CAT protein]]; Taurine inhibits the reaction [Isotretinoin results in decreased activity of CAT protein]; Taurine inhibits the reaction [Malathion results in decreased activity of CAT protein]; Taurine inhibits the reaction [Methamphetamine results in decreased activity of CAT protein]; Taurine inhibits the reaction [potassium bromate results in decreased activity of CAT protein]; Taurine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Taurine inhibits the reaction [sodium arsenite results in decreased expression of CAT protein]; Taurine inhibits the reaction [sodium arsenite results in increased activity of CAT protein]; Taurine inhibits the reaction [Sodium Fluoride results in decreased activity of CAT protein] Taurine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Taurine inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]; Taurine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:15621940 PMID:17624716 PMID:18548748 PMID:18561905 PMID:19429265 PMID:19616567 PMID:19672740 PMID:19794907 PMID:23041169 PMID:25213677 PMID:27840156 PMID:28987951 PMID:35906876 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in decreased expression of CEBPA mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions increases expression |
EXP ISO |
Taurine affects the reaction [CGA protein results in increased secretion of Testosterone] Taurine results in increased expression of CGA mRNA |
CTD |
PMID:16579726 PMID:19921479 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
EXP |
Taurine inhibits the reaction [Manganese results in decreased activity of CHAT protein] |
CTD |
PMID:24885898 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
Taurine results in decreased expression of CHN1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [sodium arsenite results in increased phosphorylation of CHUK protein] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19616567 PMID:29568078 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Taurine |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cops2 |
COP9 signalosome subunit 2 |
increases expression |
ISO |
Taurine results in increased expression of COPS2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 3:113,084,174...113,110,090
Ensembl chr 3:113,084,176...113,109,947
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
EXP |
Taurine results in increased expression of CPT1A mRNA Taurine inhibits the reaction [Sodium Glutamate results in decreased expression of CPT1A mRNA] |
CTD |
PMID:26092479 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA] |
CTD |
PMID:33368748 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
Taurine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of CTSB protein] Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of CTSB protein] |
CTD |
PMID:30237538 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
decreases expression |
ISO |
Taurine results in decreased expression of CXCR3 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
EXP |
Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYB5A protein] |
CTD |
PMID:27091720 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein] |
CTD |
PMID:29568078 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Taurine inhibits the reaction [Alloxan affects the localization of CYCS protein] |
CTD |
PMID:22138235 PMID:23092809 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:36484981 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Acetaminophen results in increased activity of CYP2E1 protein]; Taurine inhibits the reaction [Acetaminophen results in increased expression of CYP2E1 protein] |
CTD |
PMID:20067817 PMID:20166895 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dbh |
dopamine beta-hydroxylase |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenic trioxide results in decreased expression of DBH mRNA] |
CTD |
PMID:23392890 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dct |
dopachrome tautomerase |
decreases expression multiple interactions |
ISO |
Taurine results in decreased expression of DCT protein [Taurine co-treated with azelaic acid] results in decreased expression of DCT protein |
CTD |
PMID:20804622 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
ISO |
Taurine results in decreased expression of DDAH1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenite results in increased expression of DDIT3 protein] |
CTD |
PMID:25547999 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dek |
DEK proto-oncogene |
increases chemical synthesis |
ISO |
DEK protein results in increased chemical synthesis of Taurine |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dgkz |
diacylglycerol kinase zeta |
increases expression |
ISO |
Taurine results in increased expression of DGKZ mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 3:77,904,149...77,946,114
Ensembl chr 3:77,904,150...77,946,099
|
|
G |
Dmd |
dystrophin |
multiple interactions |
ISO |
Taurine inhibits the reaction [DMD gene mutant form results in increased expression of RELA protein modified form]; Taurine inhibits the reaction [DMD gene mutant form results in increased expression of SIRT1 mRNA] |
CTD |
PMID:26930420 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions increases expression |
EXP |
[Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in decreased expression of DUSP1 mRNA]; [Taurine binds to Zinc] which results in increased expression of DUSP1 mRNA; [Taurine binds to Zinc] which results in increased expression of DUSP1 protein; [Taurine co-treated with Zinc Acetate] results in increased expression of DUSP1 mRNA; [Taurine co-treated with Zinc Acetate] results in increased expression of DUSP1 protein Taurine results in increased expression of DUSP1 protein |
CTD |
PMID:26335259 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine |
CTD |
PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Taurine results in increased expression of EI24 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:30660605 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fas |
Fas cell surface death receptor |
increases secretion |
ISO |
FAS protein results in increased secretion of Taurine |
CTD |
PMID:10864002 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of FASN mRNA] |
CTD |
PMID:30237538 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of FBP1 mRNA] |
CTD |
PMID:30362509 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Taurine results in decreased expression of FGFR1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS protein] |
CTD |
PMID:33368748 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of FOXO1 mRNA] |
CTD |
PMID:30362509 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases secretion multiple interactions |
EXP |
Taurine results in increased secretion of FSHB protein Taurine inhibits the reaction [cyhalothrin results in decreased expression of FSHB protein] |
CTD |
PMID:19921479 PMID:29506456 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of G6PC1 mRNA] |
CTD |
PMID:30362509 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [Cadmium Chloride results in decreased activity of G6PD protein] [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; [Taurine co-treated with coenzyme Q10] results in increased activity of G6PD protein; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; Taurine inhibits the reaction [potassium bromate results in decreased activity of G6PD protein] |
CTD |
PMID:18548748 PMID:18561905 PMID:25213677 PMID:33548410 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of GCK mRNA] |
CTD |
PMID:30362509 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Glra1 |
glycine receptor, alpha 1 |
multiple interactions |
ISO |
Taurine binds to and results in increased activity of GLRA1 protein |
CTD |
PMID:15081878 |
|
NCBI chr10:39,625,853...39,727,897
Ensembl chr10:39,629,459...39,727,162
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [Acetaminophen results in increased expression of GPT protein]; Taurine inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Taurine inhibits the reaction [Isotretinoin results in increased expression of GPT protein] [NR1H4 protein affects the susceptibility to Taurine] which affects the activity of GPT protein; Taurine inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] |
CTD |
PMID:15931870 PMID:20166895 PMID:32062620 PMID:35906876 PMID:36310519 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grm7 |
glutamate metabotropic receptor 7 |
decreases expression |
ISO |
Taurine results in decreased expression of GRM7 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 4:143,730,862...144,613,230
Ensembl chr 4:143,731,259...144,612,344
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:30362509 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein]; Taurine inhibits the reaction [sodium arsenite results in decreased activity of GSR protein] Taurine inhibits the reaction [potassium bromate results in decreased activity of GSR protein]; Taurine inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Taurine inhibits the reaction [sodium arsenite results in decreased expression of GSR protein]; Taurine inhibits the reaction [sodium arsenite results in increased activity of GSR protein] |
CTD |
PMID:17624716 PMID:18548748 PMID:18561905 PMID:19429265 PMID:19616567 PMID:19672740 PMID:25213677 More...
|
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
decreases expression |
ISO |
Taurine results in decreased expression of GUCY1A1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gys1 |
glycogen synthase 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of GYS1 protein] |
CTD |
PMID:30362509 |
|
NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression |
ISO |
Taurine results in decreased expression of HMGB1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
[Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 mRNA]; [Taurine binds to Zinc] which results in decreased expression of HMOX1 mRNA; [Taurine binds to Zinc] which results in increased expression of HMOX1 protein; [Taurine co-treated with Zinc Acetate] results in increased expression of HMOX1 protein; Taurine inhibits the reaction [Ammonium Chloride results in increased expression of HMOX1 mRNA] [NR1H4 protein affects the susceptibility to Taurine] which affects the expression of HMOX1 mRNA Taurine results in increased expression of HMOX1 protein |
CTD |
PMID:12420312 PMID:26335259 PMID:32062620 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [Nicotine results in decreased expression of HSD17B1 protein] |
CTD |
PMID:20498001 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
multiple interactions |
ISO |
Taurine inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of HSD17B10 mRNA] |
CTD |
PMID:36484981 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
Taurine inhibits the reaction [cyhalothrin results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:29506456 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenite results in increased expression of HSPA5 protein] |
CTD |
PMID:25547999 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [nandrolone decanoate results in increased expression of ICAM1 protein] |
CTD |
PMID:25542992 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Taurine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Taurine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Taurine inhibits the reaction [Malathion results in increased expression of IFNG mRNA] |
CTD |
PMID:28987951 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression |
ISO |
Taurine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
Taurine inhibits the reaction [sodium arsenite results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:19616567 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of IL10 protein] |
CTD |
PMID:30237538 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
EXP ISO |
[[Taurine binds to Zinc] which co-treated with poly(N-vinylpyrrolidine)] results in decreased expression of IL1B protein; [Taurine co-treated with Zinc Acetate] results in decreased expression of IL1B protein; Taurine inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]; Taurine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Taurine inhibits the reaction [Malathion results in increased expression of IL1B mRNA] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] Taurine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein] Taurine results in decreased expression of IL1B protein |
CTD |
PMID:12706339 PMID:27501764 PMID:28987951 PMID:29568078 PMID:30237538 PMID:30660605 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [Alloxan results in increased expression of IL6 protein] [Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in increased secretion of IL6 protein]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein] |
CTD |
PMID:22138235 PMID:29078374 PMID:30237538 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]] |
CTD |
PMID:30660605 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insr |
insulin receptor |
multiple interactions increases phosphorylation |
EXP |
Taurine inhibits the reaction [Alloxan results in decreased phosphorylation of INSR protein] Taurine results in increased phosphorylation of INSR protein |
CTD |
PMID:22138235 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
increases phosphorylation multiple interactions |
EXP ISO |
Taurine results in increased phosphorylation of IRS1 protein Taurine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of IRS1 protein] Taurine inhibits the reaction [Alloxan results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:22138235 PMID:30362509 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN protein] |
CTD |
PMID:33368748 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Krit1 |
KRIT1, ankyrin repeat containing |
increases expression |
ISO |
Taurine results in increased expression of KRIT1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of LAMP1 protein] |
CTD |
PMID:30237538 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lancl1 |
LanC like glutathione S-transferase 1 |
increases expression |
ISO |
Taurine results in increased expression of LANCL1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 9:68,515,052...68,548,646
Ensembl chr 9:68,518,574...68,548,628
|
|
G |
Ldhc |
lactate dehydrogenase C |
multiple interactions increases activity |
EXP |
[Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; [Taurine co-treated with coenzyme Q10] results in increased activity of LDHC protein; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; Taurine inhibits the reaction [Nandrolone Decanoate results in decreased activity of LDHC protein] Taurine results in increased activity of LDHC protein |
CTD |
PMID:25542992 PMID:33548410 |
|
NCBI chr 1:97,385,984...97,403,382
Ensembl chr 1:97,382,379...97,403,378
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of Taurine |
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases secretion multiple interactions |
EXP |
Taurine results in increased secretion of LHB protein Taurine inhibits the reaction [cyhalothrin results in decreased expression of LHB protein] |
CTD |
PMID:19921479 PMID:29506456 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Taurine results in decreased expression of LYN mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of MAP1LC3B protein] |
CTD |
PMID:30237538 PMID:30677399 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases expression |
ISO EXP |
[Taurine co-treated with azelaic acid] results in increased phosphorylation of and results in increased activity of MAPK1 protein Taurine results in decreased expression of MAPK1 protein modified form [[Taurine binds to Zinc] which co-treated with poly(N-vinylpyrrolidine)] results in decreased expression of MAPK1 protein modified form; Taurine inhibits the reaction [sodium arsenite results in increased expression of MAPK1 protein modified form]; Taurine inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19429265 PMID:19672740 PMID:20804622 PMID:27501764 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[Taurine co-treated with azelaic acid] results in increased phosphorylation of and results in increased activity of MAPK3 protein Taurine inhibits the reaction [sodium arsenite results in increased expression of MAPK3 protein modified form]; Taurine inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19429265 PMID:19672740 PMID:20804622 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions decreases expression |
EXP |
[[Taurine binds to Zinc] which co-treated with poly(N-vinylpyrrolidine)] results in decreased expression of MAPK8 protein modified form; [Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in increased expression of MAPK8 mRNA]; [Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK8 protein]; [Taurine binds to Zinc] which results in decreased expression of MAPK8 mRNA; [Taurine co-treated with Zinc Acetate] results in decreased expression of MAPK8 protein modified form; Taurine inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK8 protein] Taurine results in decreased expression of MAPK8 protein modified form |
CTD |
PMID:26335259 PMID:27501764 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions decreases expression |
EXP |
[[Taurine binds to Zinc] which co-treated with poly(N-vinylpyrrolidine)] results in decreased expression of MAPK9 protein modified form; [Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK9 protein]; [Taurine co-treated with Zinc Acetate] results in decreased expression of MAPK9 protein modified form; Taurine inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK9 protein] Taurine results in decreased expression of MAPK9 protein modified form |
CTD |
PMID:26335259 PMID:27501764 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions decreases expression |
ISO |
[Taurine co-treated with azelaic acid] results in decreased expression of MITF protein Taurine results in decreased expression of MITF protein |
CTD |
PMID:20804622 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
EXP |
Taurine inhibits the reaction [Sodium Glutamate results in decreased expression of MLXIPL mRNA] |
CTD |
PMID:26092479 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Taurine inhibits the reaction [nandrolone decanoate results in increased expression of MMP9 mRNA] |
CTD |
PMID:25542992 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [Alloxan results in increased activity of MPO protein]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of MPO protein] |
CTD |
PMID:22138235 PMID:30237538 PMID:30660605 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Ms4a6a |
membrane spanning 4-domains A6A |
decreases expression |
ISO |
Taurine results in decreased expression of MS4A6A mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:208,401,465...208,414,831
Ensembl chr 1:208,401,466...208,414,758
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Taurine inhibits the reaction [Methamphetamine results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:23041169 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
Taurine inhibits the reaction [Sodium Glutamate results in decreased expression of MTTP mRNA] |
CTD |
PMID:26092479 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein] |
CTD |
PMID:29568078 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenite results in decreased expression of NDRG4 mRNA] |
CTD |
PMID:23744399 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
multiple interactions |
ISO |
[Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA1 mRNA] [3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA1 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
|
|
G |
Ndufa2 |
NADH:ubiquinone oxidoreductase subunit A2 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA2 mRNA] Taurine promotes the reaction [3-methyladenine inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA2 mRNA]] |
CTD |
PMID:29078374 |
|
NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
|
|
G |
Ndufc2 |
NADH:ubiquinone oxidoreductase subunit C2 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFC2 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 1:151,711,965...151,718,188
Ensembl chr 1:151,711,901...151,718,189
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFS4 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [sodium arsenite results in decreased expression of NFKBIA protein] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:19429265 PMID:29568078 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Taurine inhibits the reaction [hexabromocyclododecane affects the expression of NGF protein] |
CTD |
PMID:28849449 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of NLRP3 protein] Taurine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein] |
CTD |
PMID:30237538 PMID:30660605 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA] |
CTD |
PMID:19362168 PMID:29568078 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects response to substance multiple interactions |
ISO |
NR1H4 protein affects the susceptibility to Taurine [NR1H4 protein affects the susceptibility to Taurine] which affects the activity of GPT protein; [NR1H4 protein affects the susceptibility to Taurine] which affects the expression of ACACA mRNA; [NR1H4 protein affects the susceptibility to Taurine] which affects the expression of GSTA1 mRNA; [NR1H4 protein affects the susceptibility to Taurine] which affects the expression of HMOX1 mRNA; [NR1H4 protein affects the susceptibility to Taurine] which affects the expression of SCD1 mRNA |
CTD |
PMID:32062620 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Olr59 |
olfactory receptor 59 |
decreases expression |
ISO |
Taurine results in decreased expression of OR51E2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179
|
|
G |
Pag1 |
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 |
decreases expression |
ISO |
Taurine results in decreased expression of PAG1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 2:91,935,378...92,076,937
Ensembl chr 2:92,057,216...92,069,849
|
|
G |
Pak4 |
p21 (RAC1) activated kinase 4 |
decreases expression |
ISO |
Taurine results in decreased expression of PAK4 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:83,849,904...83,889,188
Ensembl chr 1:83,849,904...83,859,413
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein]; Taurine inhibits the reaction [sodium arsenite results in increased degradation of PARP1 protein] |
CTD |
PMID:19616567 PMID:20830294 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of PCK1 mRNA] |
CTD |
PMID:30362509 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA protein] |
CTD |
PMID:27091720 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
EXP |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of PINK1 protein]; Taurine inhibits the reaction [sodium arsenite results in decreased expression of PINK1 protein] |
CTD |
PMID:30551535 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of PKLR mRNA] |
CTD |
PMID:30362509 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Polb |
DNA polymerase beta |
increases expression |
ISO |
Taurine results in increased expression of POLB mRNA |
CTD |
PMID:16579726 |
|
NCBI chr16:69,379,438...69,402,710
Ensembl chr16:69,379,400...69,404,812
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
increases expression |
ISO |
Taurine results in increased expression of POLD1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
ISO |
Taurine results in increased expression of POLM mRNA |
CTD |
PMID:16579726 |
|
NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of PPARA protein] |
CTD |
PMID:30677399 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [sodium arsenite results in decreased expression of PPARG protein] Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of PPARG protein] |
CTD |
PMID:30362509 PMID:30551535 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of PPARGC1A mRNA] [Taurine co-treated with Sodium Glutamate] results in increased expression of PPARGC1A mRNA; [Taurine co-treated with Sodium Glutamate] results in increased expression of PPARGC1A protein; Taurine promotes the reaction [Sodium Glutamate results in increased expression of PPARGC1A protein] |
CTD |
PMID:25211138 PMID:30362509 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1r16b |
protein phosphatase 1, regulatory subunit 16B |
increases expression |
ISO |
Taurine results in increased expression of PPP1R16B mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 3:147,323,652...147,419,658
Ensembl chr 3:147,324,126...147,418,937
|
|
G |
Ppp2r5e |
protein phosphatase 2 regulatory subunit B', epsilon |
decreases expression |
ISO |
Taurine results in decreased expression of PPP2R5E mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 6:94,168,846...94,317,872
Ensembl chr 6:94,168,846...94,317,872
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA] |
CTD |
PMID:33368748 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
decreases expression |
ISO |
Taurine results in decreased expression of PRKAR2B mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prkca |
protein kinase C, alpha |
decreases expression |
EXP |
Taurine results in decreased expression of PRKCA protein |
CTD |
PMID:18822960 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
EXP |
Taurine inhibits the reaction [sodium arsenite results in increased expression of and results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:20830294 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of PRKN protein] |
CTD |
PMID:30551535 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Psen2 |
presenilin 2 |
decreases expression |
ISO |
Taurine results in decreased expression of PSEN2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Ptprk |
protein tyrosine phosphatase, receptor type, K |
decreases expression |
ISO |
Taurine results in decreased expression of PTPRK mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:16,738,896...17,236,687
Ensembl chr 1:16,850,576...17,103,605
|
|
G |
Rab5a |
RAB5A, member RAS oncogene family |
decreases expression |
ISO |
Taurine results in decreased expression of RAB5A mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873
|
|
G |
Rad51c |
RAD51 paralog C |
increases expression |
ISO |
Taurine results in increased expression of RAD51C mRNA |
CTD |
PMID:16579726 |
|
NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
|
|
G |
Rad9a |
RAD9 checkpoint clamp component A |
increases expression |
ISO |
Taurine results in increased expression of RAD9A mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:201,488,511...201,553,582
Ensembl chr 1:201,487,136...201,553,608
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Taurine results in decreased expression of RAPGEF2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
increases expression |
ISO |
Taurine results in increased expression of RASGRP1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 3:104,168,549...104,230,107
Ensembl chr 3:104,170,013...104,230,056
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [Alloxan results in increased expression of RELA protein]; Taurine inhibits the reaction [Malathion results in increased expression of RELA mRNA]; Taurine inhibits the reaction [sodium arsenite results in increased expression of RELA protein]; Taurine inhibits the reaction [sodium arsenite results in increased phosphorylation of RELA protein] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein]; Taurine inhibits the reaction [DMD gene mutant form results in increased expression of RELA protein modified form] |
CTD |
PMID:19429265 PMID:19616567 PMID:19672740 PMID:22138235 PMID:26930420 PMID:28987951 PMID:29568078 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Taurine results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[NR1H4 protein affects the susceptibility to Taurine] which affects the expression of SCD1 mRNA |
CTD |
PMID:32062620 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scg5 |
secretogranin V |
increases expression |
ISO |
Taurine results in increased expression of SCG5 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 3:100,544,101...100,588,558
Ensembl chr 3:100,544,099...100,588,463
|
|
G |
Sdha |
succinate dehydrogenase complex flavoprotein subunit A |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenic trioxide results in decreased expression of SDHA protein] |
CTD |
PMID:19422848 |
|
NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression |
ISO |
Taurine inhibits the reaction [arsenite results in decreased expression of SIRT1 mRNA] Taurine results in increased expression of SIRT1 mRNA; Taurine results in increased expression of SIRT1 protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Taurine results in increased expression of SIRT1 mRNA]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Taurine results in increased expression of SIRT1 protein]; Taurine inhibits the reaction [DMD gene mutant form results in increased expression of SIRT1 mRNA] |
CTD |
PMID:23744399 PMID:26930420 PMID:32017914 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
affects localization multiple interactions |
EXP ISO |
Taurine affects the localization of SLC2A2 protein Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of SLC2A2 protein] |
CTD |
PMID:23092809 PMID:30362509 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
affects localization multiple interactions |
EXP |
Taurine affects the localization of SLC2A4 protein Taurine inhibits the reaction [Alloxan affects the localization of SLC2A4 protein] |
CTD |
PMID:22138235 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a6 |
solute carrier family 6 member 6 |
increases expression |
ISO |
Taurine results in increased expression of SLC6A6 protein |
CTD |
PMID:32017914 |
|
NCBI chr 4:124,195,186...124,268,880
Ensembl chr 4:124,195,218...124,268,875
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of Taurine |
CTD |
PMID:21561886 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
increases expression |
ISO |
Taurine results in increased expression of SMC3 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
|
|
G |
Snapc5 |
small nuclear RNA activating complex, polypeptide 5 |
increases expression |
ISO |
Taurine results in increased expression of SNAPC5 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 8:64,677,204...64,680,769
Ensembl chr 8:64,677,205...64,681,964
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
Taurine inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]] |
CTD |
PMID:29568078 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Spry2 |
sprouty RTK signaling antagonist 2 |
increases expression |
ISO |
Taurine results in increased expression of SPRY2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein] Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of SQSTM1 protein] |
CTD |
PMID:30237538 PMID:30362509 PMID:30551535 PMID:30677399 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srp54a |
signal recognition particle 54A |
decreases expression |
ISO |
Taurine results in decreased expression of SRP54 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 6:72,587,584...72,626,878
Ensembl chr 6:72,587,605...72,625,189
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [cyhalothrin results in decreased expression of STAR mRNA]; Taurine inhibits the reaction [cyhalothrin results in decreased expression of STAR protein]; Taurine inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Taurine inhibits the reaction [Nicotine results in decreased expression of STAR protein] Taurine inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of STAR mRNA] |
CTD |
PMID:20498001 PMID:29506456 PMID:36484981 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases expression |
ISO |
Taurine results in decreased expression of STAT3 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tacr1 |
tachykinin receptor 1 |
decreases expression |
ISO |
Taurine results in decreased expression of TACR1 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Tek |
TEK receptor tyrosine kinase |
increases expression |
ISO |
Taurine results in increased expression of TEK mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
Taurine inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 mRNA]; Taurine inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein] [Taurine co-treated with epigallocatechin gallate co-treated with Genistein] inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Taurine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Taurine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] |
CTD |
PMID:15893842 PMID:15931870 PMID:19337903 PMID:25448286 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenic trioxide results in decreased expression of TH mRNA] |
CTD |
PMID:23392890 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenic trioxide results in decreased expression of THRB mRNA]; Taurine inhibits the reaction [arsenic trioxide results in decreased expression of THRB protein] |
CTD |
PMID:23392932 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Taurine inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; Taurine inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; Taurine inhibits the reaction [Alloxan results in increased expression of TNF protein]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; Taurine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Taurine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Taurine inhibits the reaction [Malathion results in increased expression of TNF mRNA]; Taurine inhibits the reaction [Nandrolone Decanoate results in increased expression of TNF protein]; Taurine inhibits the reaction [sodium arsenite results in increased expression of TNF protein]; Taurine inhibits the reaction [sodium arsenite results in increased secretion of TNF protein] Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Taurine inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein] |
CTD |
PMID:12706339 PMID:19362168 PMID:19429265 PMID:19672740 PMID:20166895 PMID:22138235 PMID:25542992 PMID:28987951 PMID:29568078 PMID:30237538 PMID:30660605 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Taurine inhibits the reaction [aluminum phosphide results in increased expression of TNNI3 protein] |
CTD |
PMID:34139304 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of TRP53 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of TRP53 protein] |
CTD |
PMID:30101532 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
decreases expression |
ISO |
Taurine results in decreased expression of TP53I3 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
multiple interactions |
ISO |
Taurine inhibits the reaction [arsenic trioxide results in decreased expression of TPH1 mRNA] |
CTD |
PMID:23392890 |
|
NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344
|
|
G |
Tyk2 |
tyrosine kinase 2 |
decreases expression |
ISO |
Taurine results in decreased expression of TYK2 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 8:19,641,881...19,667,157
Ensembl chr 8:19,641,884...19,667,044
|
|
G |
Tyr |
tyrosinase |
multiple interactions decreases expression |
ISO |
[Taurine co-treated with azelaic acid] results in decreased activity of TYR protein; [Taurine co-treated with azelaic acid] results in decreased expression of TYR protein Taurine results in decreased expression of TYR protein |
CTD |
PMID:20804622 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
multiple interactions decreases expression |
ISO |
[Taurine co-treated with azelaic acid] results in decreased expression of TYRP1 protein Taurine results in decreased expression of TYRP1 protein |
CTD |
PMID:20804622 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
EXP |
[Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in decreased expression of UGT1A1 mRNA]; [Taurine binds to Zinc] which results in decreased expression of UGT1A1 mRNA |
CTD |
PMID:26335259 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
multiple interactions |
EXP |
[Taurine binds to Zinc] inhibits the reaction [Doxorubicin results in decreased expression of UGT2B1 mRNA]; [Taurine binds to Zinc] which results in increased expression of UGT2B1 mRNA; [Taurine co-treated with Zinc Acetate] results in increased expression of UGT2B1 mRNA |
CTD |
PMID:26335259 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Vcp |
valosin-containing protein |
decreases expression |
ISO |
Taurine results in decreased expression of VCP mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Taurine inhibits the reaction [Streptozocin results in decreased expression of VEGFA mRNA] |
CTD |
PMID:11596663 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
Taurine inhibits the reaction [Alloxan results in increased activity of XDH protein]; Taurine inhibits the reaction [potassium bromate results in increased activity of XDH protein] |
CTD |
PMID:22138235 PMID:25213677 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
increases expression |
ISO |
Taurine results in increased expression of XRCC4 mRNA |
CTD |
PMID:16579726 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression multiple interactions |
EXP |
tauromuricholic acid results in increased expression of ABCB11 protein tauromuricholic acid results in increased expression of and results in increased activity of ABCB11 protein |
CTD |
PMID:11672435 PMID:12644037 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
EXP |
tauromuricholic acid results in increased expression of ABCC2 protein tauromuricholic acid results in increased expression of and results in increased activity of ABCC2 protein |
CTD |
PMID:11672435 PMID:12644037 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
tauromuricholic acid results in increased expression of ABCC3 protein |
CTD |
PMID:11672435 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases secretion increases abundance |
ISO |
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin affects the secretion of tauromuricholic acid] AHR gene mutant form results in increased secretion of tauromuricholic acid AHR gene mutant form results in increased abundance of tauromuricholic acid |
CTD |
PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA |
CTD |
PMID:22098667 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA |
CTD |
PMID:22098667 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of tauromuricholic acid |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA |
CTD |
PMID:22098667 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
increases abundance |
ISO |
IL10 gene mutant form results in increased abundance of tauromuricholic acid |
CTD |
PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects abundance |
ISO |
NR1H4 protein affects the abundance of tauromuricholic acid |
CTD |
PMID:30556042 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases abundance |
ISO |
[PPARA gene mutant form results in increased susceptibility to Clofibrate] which results in increased abundance of tauromuricholic acid; PPARA gene mutant form inhibits the reaction [Gemfibrozil results in increased abundance of tauromuricholic acid] PPARA gene mutant form results in increased abundance of tauromuricholic acid |
CTD |
PMID:24385052 PMID:29175453 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
tauromuricholic acid results in increased expression of SLC10A2 protein |
CTD |
PMID:11672435 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Smad3 |
SMAD family member 3 |
increases abundance |
ISO |
SMAD3 protein results in increased abundance of tauromuricholic acid |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
affects transport increases expression |
ISO EXP |
ABCB11 protein affects the transport of Taurochenodeoxycholic Acid Taurochenodeoxycholic Acid results in increased expression of ABCB11 protein |
CTD |
PMID:11343252 PMID:11672435 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Taurochenodeoxycholic Acid results in increased expression of ABCC2 protein |
CTD |
PMID:11672435 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Taurochenodeoxycholic Acid results in increased expression of ABCC3 protein |
CTD |
PMID:11672435 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases secretion increases abundance |
ISO |
AHR gene mutant form results in increased secretion of Taurochenodeoxycholic Acid AHR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid |
CTD |
PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases hydroxylation |
ISO |
CYP3A4 protein results in increased hydroxylation of Taurochenodeoxycholic Acid |
CTD |
PMID:36473578 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of Taurochenodeoxycholic Acid |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Taurochenodeoxycholic Acid results in increased phosphorylation of and results in decreased activity of GSK3B protein |
CTD |
PMID:20512997 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
Taurochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] |
CTD |
PMID:15802798 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Il10 |
interleukin 10 |
increases abundance |
ISO |
IL10 gene mutant form results in increased abundance of Taurochenodeoxycholic Acid |
CTD |
PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases abundance |
ISO |
POR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
Taurochenodeoxycholic Acid results in increased expression of SLC10A2 protein |
CTD |
PMID:11672435 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc51a |
solute carrier family 51 member A |
multiple interactions |
ISO |
[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] |
CTD |
PMID:32294204 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] |
CTD |
PMID:32294204 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Smad3 |
SMAD family member 3 |
increases abundance |
ISO |
SMAD3 protein results in increased abundance of Taurochenodeoxycholic Acid |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Taurochenodeoxycholic Acid results in increased expression of TGFB1 protein |
CTD |
PMID:8743917 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Taurochenodeoxycholic Acid results in increased expression of TNF protein |
CTD |
PMID:8743917 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
affects transport |
ISO |
ABCA8 protein affects the transport of Taurocholic Acid |
CTD |
PMID:12379217 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
affects import decreases transport increases uptake increases expression multiple interactions increases transport increases export affects transport increases import affects secretion decreases uptake |
ISO EXP |
ABCB11 protein affects the import of Taurocholic Acid ABCB11 protein mutant form results in decreased transport of Taurocholic Acid ABCB11 protein results in increased uptake of Taurocholic Acid Taurocholic Acid results in increased expression of ABCB11 mRNA 2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction [ABCB11 protein results in increased import of Taurocholic Acid]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Amiodarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Benzbromarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Celecoxib inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diclofenac inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diethylstilbestrol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Disulfiram inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Elacridar inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Felodipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fenofibrate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Imatinib Mesylate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indomethacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Isradipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid]; Lopinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Mifepristone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Naproxen inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; nefazodone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nelfinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nicardipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrendipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; olmesartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ranolazine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; repaglinide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosiglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Saquinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Silymarin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; simvastatin acid inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Spironolactone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfinpyrazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Terfenadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Tinidazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; tipranavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; verlukast inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] ABCB11 protein affects the transport of Taurocholic Acid 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside affects the reaction [[Emodin affects the activity of ABCB11 protein] which affects the export of Taurocholic Acid]; [Emodin affects the activity of ABCB11 protein] which affects the export of Taurocholic Acid; GLPG1837 inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]; ivacaftor inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]; Taurocholic Acid results in increased expression of and results in increased activity of ABCB11 protein; Troglitazone inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; troglitazone sulfate inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid] Taurocholic Acid results in increased expression of ABCB11 protein ABCB11 protein affects the secretion of Taurocholic Acid ABCB11 protein results in decreased uptake of Taurocholic Acid ABCB11 protein affects the transport of Taurocholic Acid; ABCB11 protein mutant form affects the transport of Taurocholic Acid |
CTD |
PMID:10617675 PMID:11113123 PMID:11179459 PMID:11557132 PMID:12518026 PMID:12642476 PMID:12644037 PMID:12865277 PMID:14672610 PMID:14724752 PMID:15465654 PMID:15791618 PMID:15901796 PMID:16039748 PMID:19223659 PMID:20147439 PMID:20829430 PMID:24014644 PMID:25862123 PMID:27160211 PMID:27676153 PMID:30639138 PMID:31348918 PMID:35753641 PMID:36142670 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP ISO |
Taurocholic Acid results in increased expression of ABCB1 protein Taurocholic Acid results in increased expression of ABCB1A mRNA |
CTD |
PMID:11113123 PMID:27160211 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
EXP |
Taurocholic Acid results in increased expression of ABCB4 protein |
CTD |
PMID:11113123 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Taurocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16101123 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases activity increases expression multiple interactions |
EXP ISO |
Taurocholic Acid results in increased activity of ABCC2 protein; Taurocholic Acid results in increased activity of ABCC2 protein modified form Taurocholic Acid results in increased expression of ABCC2 mRNA Taurocholic Acid results in increased expression of and results in increased activity of ABCC2 protein |
CTD |
PMID:12644037 PMID:15904671 PMID:27160211 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases activity multiple interactions increases uptake affects transport |
ISO EXP |
Taurocholic Acid results in increased activity of ABCC3 protein 4-cresylglucuronide promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]; hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid] ABCC3 protein affects the transport of Taurocholic Acid |
CTD |
PMID:11557524 PMID:17569508 PMID:30639138 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of ABCG2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases secretion |
ISO |
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurocholic Acid] AHR gene mutant form results in increased secretion of Taurocholic Acid |
CTD |
PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]] |
CTD |
PMID:12388182 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
ISO |
Taurocholic Acid results in decreased expression of APOA1 protein |
CTD |
PMID:19445040 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions |
EXP |
[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein |
CTD |
PMID:6631239 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein |
CTD |
PMID:6631239 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO |
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein] |
CTD |
PMID:18512153 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Taurocholic Acid results in increased expression of BLVRA mRNA |
CTD |
PMID:18706437 |
|
NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
EXP |
Taurocholic Acid results in increased expression of BNIP3L mRNA; Taurocholic Acid results in increased expression of BNIP3L protein |
CTD |
PMID:14530762 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] |
CTD |
PMID:12388182 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] |
CTD |
PMID:12388182 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP9 protein] |
CTD |
PMID:12388182 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cav1 |
caveolin 1 |
increases secretion |
ISO |
CAV1 protein results in increased secretion of Taurocholic Acid |
CTD |
PMID:14647059 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav2 |
caveolin 2 |
increases secretion |
ISO |
CAV2 protein results in increased secretion of Taurocholic Acid |
CTD |
PMID:14647059 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] |
CTD |
PMID:21224055 PMID:28505368 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA] |
CTD |
PMID:21224055 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CCL3 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CCL4 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CCL5 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA] |
CTD |
PMID:21224055 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein] Taurocholic Acid results in increased expression of CCND1 mRNA; Taurocholic Acid results in increased expression of CCND1 protein |
CTD |
PMID:18512153 PMID:18840136 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions increases expression |
ISO |
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] |
CTD |
PMID:18512153 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cel |
carboxyl ester lipase |
multiple interactions |
ISO |
Taurocholic Acid inhibits the reaction [Polyphenols results in decreased activity of CEL protein] |
CTD |
PMID:16099206 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects uptake increases activity |
ISO |
CFTR protein mutant form affects the uptake of Taurocholic Acid Taurocholic Acid results in increased activity of CFTR protein |
CTD |
PMID:15099439 PMID:16037545 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA] |
CTD |
PMID:21224055 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CSF3 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CXCL10 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CXCL11 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA] |
CTD |
PMID:21224055 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of CXCL16 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Taurocholic Acid results in increased expression of CXCL2 mRNA; Taurocholic Acid results in increased expression of CXCL2 protein [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein] |
CTD |
PMID:21224055 PMID:22098667 PMID:26176423 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Taurocholic Acid results in increased expression of CXCL1 mRNA [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA] |
CTD |
PMID:21224055 PMID:22098667 PMID:26176423 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Taurocholic Acid results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:7832767 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
decreases activity |
EXP |
Taurocholic Acid results in decreased activity of CYP2A1 protein |
CTD |
PMID:8889968 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
Taurocholic Acid results in decreased activity of CYP2C11 protein |
CTD |
PMID:8889968 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
EXP |
Taurocholic Acid results in decreased activity of CYP3A2 protein [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Taurocholic Acid |
CTD |
PMID:8889968 PMID:34461081 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Taurocholic Acid |
CTD |
PMID:34461081 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
ISO EXP |
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:7832767 PMID:16284190 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases activity decreases expression |
EXP |
Taurocholic Acid results in decreased activity of CYP7B1 protein Taurocholic Acid results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:12029625 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26518876 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein] Taurocholic Acid results in increased expression of EGR1 mRNA; Taurocholic Acid results in increased expression of EGR1 protein |
CTD |
PMID:21224055 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of Taurocholic Acid |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions increases expression |
ISO |
[Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA Taurocholic Acid results in increased expression of FGF15 mRNA |
CTD |
PMID:16284190 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
multiple interactions |
ISO |
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] |
CTD |
PMID:16284190 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Hgf |
hepatocyte growth factor |
increases uptake |
EXP |
HGF protein results in increased uptake of Taurocholic Acid |
CTD |
PMID:18031729 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases secretion |
ISO |
HNF4A protein results in increased secretion of Taurocholic Acid |
CTD |
PMID:27160211 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
EXP ISO |
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 protein] Taurocholic Acid results in increased expression of ICAM1 mRNA; Taurocholic Acid results in increased expression of ICAM1 protein [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein] |
CTD |
PMID:19237016 PMID:21224055 PMID:22098667 PMID:26176423 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
increases expression increases abundance |
ISO |
Taurocholic Acid results in increased expression of IL10 mRNA IL10 gene mutant form results in increased abundance of Taurocholic Acid |
CTD |
PMID:21224055 PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions decreases import |
ISO EXP |
Taurocholic Acid results in increased expression of IL1B mRNA [TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid IL1B protein results in decreased import of Taurocholic Acid astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] Taurocholic Acid results in increased expression of IL1B mRNA; Taurocholic Acid results in increased expression of IL1B protein EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA] |
CTD |
PMID:21224055 PMID:25604657 PMID:30876886 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases import increases expression |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA] IL6 protein results in decreased import of Taurocholic Acid [TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA] Taurocholic Acid results in increased expression of IL6 mRNA; Taurocholic Acid results in increased expression of IL6 protein |
CTD |
PMID:20035747 PMID:20382593 PMID:25604657 PMID:26518876 PMID:30876886 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kl |
Klotho |
multiple interactions |
ISO |
Taurocholic Acid inhibits the reaction [KL protein results in increased hydrolysis of Glucuronides] |
CTD |
PMID:14701853 |
|
NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of KLF4 mRNA |
CTD |
PMID:27151938 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Taurocholic Acid results in increased expression of MAP1LC3B protein |
CTD |
PMID:24189133 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26518876 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18512153 PMID:26518876 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:28505368 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:28505368 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir488 |
microRNA 488 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of MIR488 mRNA |
CTD |
PMID:28851649 |
|
NCBI chr13:70,683,064...70,683,142
Ensembl chr13:70,683,064...70,683,142
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein] Taurocholic Acid results in increased expression of MMP2 mRNA; Taurocholic Acid results in increased expression of MMP2 protein |
CTD |
PMID:26518876 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein] Taurocholic Acid results in increased expression of MMP9 mRNA; Taurocholic Acid results in increased expression of MMP9 protein |
CTD |
PMID:26518876 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity increases expression |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] Taurocholic Acid results in increased expression of MPO protein |
CTD |
PMID:16440434 PMID:20035747 PMID:25604657 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
ISO |
Taurocholic Acid results in increased expression of MYC protein [NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA Taurocholic Acid results in increased expression of MYC mRNA sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein] |
CTD |
PMID:18512153 PMID:27151938 PMID:30556042 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nanog |
Nanog homeobox |
increases expression |
ISO |
Taurocholic Acid results in increased expression of NANOG mRNA |
CTD |
PMID:27151938 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of NFE2L2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases expression |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] Taurocholic Acid results in decreased expression of NFKBIA mRNA; Taurocholic Acid results in decreased expression of NFKBIA protein |
CTD |
PMID:25604657 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions decreases expression |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] Taurocholic Acid results in decreased expression of NFKBIB mRNA; Taurocholic Acid results in decreased expression of NFKBIB protein |
CTD |
PMID:25604657 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:16389574 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of NR0B2 mRNA |
CTD |
PMID:18706437 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions affects response to substance affects abundance increases expression increases export increases activity |
ISO |
epiallopregnanolone sulfate inhibits the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; GW 4064 promotes the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; Taurocholic Acid binds to and results in increased activity of NR1H4 protein NR1H4 protein affects the susceptibility to Taurocholic Acid NR1H4 protein affects the abundance of Taurocholic Acid Taurocholic Acid results in increased expression of NR1H4 mRNA Taurocholic Acid results in increased activity of NR1H4 protein [NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA; [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] |
CTD |
PMID:16284190 PMID:17567710 PMID:18706437 PMID:19445040 PMID:22961653 PMID:27160211 PMID:28505368 PMID:30556042 More...
|
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of NR1I2 mRNA |
CTD |
PMID:18706437 PMID:27160211 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases expression |
ISO |
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene binds to and affects the activity of NR1I3 protein] which results in decreased abundance of Taurocholic Acid Taurocholic Acid results in increased expression of NR1I3 mRNA |
CTD |
PMID:26984780 PMID:27160211 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pnlip |
pancreatic lipase |
increases activity multiple interactions |
EXP |
Taurocholic Acid results in increased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] |
CTD |
PMID:11668201 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions decreases expression |
ISO |
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] |
CTD |
PMID:16284190 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Por |
cytochrome p450 oxidoreductase |
decreases abundance |
ISO |
POR gene mutant form results in decreased abundance of Taurocholic Acid |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of POU5F1 mRNA |
CTD |
PMID:27151938 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases abundance |
ISO |
PPARA gene mutant form results in decreased abundance of Taurocholic Acid |
CTD |
PMID:29175453 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Taurocholic Acid results in increased expression of PTGS2 mRNA Taurocholic Acid results in increased expression of PTGS2 protein JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; MK 2206 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein] |
CTD |
PMID:21224055 PMID:26518876 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
decreases expression |
ISO |
Taurocholic Acid results in decreased expression of RAB7 protein |
CTD |
PMID:24189133 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation affects localization |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] Taurocholic Acid results in increased phosphorylation of RELA protein Taurocholic Acid affects the localization of RELA protein modified form JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form] |
CTD |
PMID:25604657 PMID:26518876 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
multiple interactions |
ISO |
S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; Taurocholic Acid results in increased activity of and results in increased uptake of S1PR2 protein |
CTD |
PMID:26518876 |
|
NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:28505368 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions increases expression increases transport increases import increases uptake |
EXP ISO |
Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid] Taurocholic Acid results in increased expression of SLC10A1 mRNA 4-cresol sulfate inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; [Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid; Acetamides analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Acetanilides analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Anthraquinones analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; bisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; bisphenol F inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Piperazines analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Sodium deficiency inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]; Sulfobromophthalein inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green]; Taurocholic Acid promotes the reaction [SLC10A1 protein results in increased uptake of Fluorescein-5-isothiocyanate]; tetrabromobisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; tetrahydrophthalamic acid analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid] |
CTD |
PMID:19464309 PMID:22641618 PMID:23850984 PMID:25106415 PMID:25319728 PMID:25862123 PMID:27160211 PMID:27450509 PMID:27676153 PMID:27989701 PMID:29024779 PMID:30639138 PMID:32209977 More...
|
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
multiple interactions increases transport increases uptake |
EXP ISO |
Bile Acids and Salts inhibits the reaction [SLC10A2 protein results in increased uptake of Taurocholic Acid] Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:19464309 PMID:25466967 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
multiple interactions decreases activity |
EXP |
Taurocholic Acid inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate] Taurocholic Acid results in decreased activity of SLC19A1 protein |
CTD |
PMID:14612385 |
|
NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:11602689 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
affects transport |
ISO |
SLC22A8 protein affects the transport of Taurocholic Acid |
CTD |
PMID:11306713 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc23a1 |
solute carrier family 23 member 1 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of SLC23A1 mRNA |
CTD |
PMID:18706437 |
|
NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of SLC23A2 mRNA |
CTD |
PMID:18706437 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc51a |
solute carrier family 51 member A |
multiple interactions |
ISO |
[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] |
CTD |
PMID:32294204 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] |
CTD |
PMID:32294204 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects uptake multiple interactions increases uptake increases expression affects transport |
ISO EXP |
SLCO1A4 protein affects the uptake of Taurocholic Acid Bile Acids and Salts inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] Taurocholic Acid results in increased expression of SLCO1A4 mRNA SLCO1A4 protein affects the transport of Taurocholic Acid |
CTD |
PMID:19464309 PMID:19833843 PMID:21561886 PMID:27160211 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases expression increases uptake |
EXP ISO |
Bile Acids and Salts inhibits the reaction [SLCO1B3 protein results in increased uptake of Taurocholic Acid] Taurocholic Acid results in increased expression of SLCO1B2 mRNA Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid] |
CTD |
PMID:19464309 PMID:26134461 PMID:27160211 PMID:30639138 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases uptake multiple interactions |
ISO |
SLCO2B1 protein results in increased uptake of Taurocholic Acid Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:24285294 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] Taurocholic Acid results in decreased expression of SOD1 mRNA; Taurocholic Acid results in decreased expression of SOD1 protein |
CTD |
PMID:25604657 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] Taurocholic Acid results in increased expression of SOD2 mRNA astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA] |
CTD |
PMID:22316666 PMID:25604657 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sort1 |
sortilin 1 |
increases sulfation |
ISO |
SORT1 gene mutant form results in increased sulfation of Taurocholic Acid |
CTD |
PMID:28453831 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of SOX2 mRNA |
CTD |
PMID:27151938 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Taurocholic Acid results in increased expression of SQSTM1 protein |
CTD |
PMID:24189133 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases phosphorylation multiple interactions |
EXP |
Taurocholic Acid results in increased phosphorylation of STAT1 protein rosiglitazone inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:19563079 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
ISO |
sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:18512153 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases transport decreases import increases expression |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA] TNF protein results in decreased transport of Taurocholic Acid TNF protein results in decreased import of Taurocholic Acid [TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA] Taurocholic Acid results in increased expression of TNF mRNA; Taurocholic Acid results in increased expression of TNF protein |
CTD |
PMID:16389574 PMID:19080501 PMID:19237016 PMID:19563079 PMID:20035747 PMID:20382593 PMID:25604657 PMID:26518876 PMID:30876886 PMID:37315771 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression increases expression |
ISO |
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA] Taurocholic Acid results in decreased expression of VCAM1 protein |
CTD |
PMID:21224055 PMID:26176423 PMID:28851649 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions increases abundance increases transport |
ISO EXP |
[Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Ketoconazole results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [Troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; Aconitine inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; aurantio-obtusin inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; carboxyatractyloside inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; cryptotanshinone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; dihydrotanshinone I inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; diosbulbin B metabolite inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; diosbulbin B promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Enzymes and Coenzymes inhibits the reaction [celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [diosbulbin B promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [isobavachalcone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [rhein promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [saikosaponin D analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [saikosaponin D inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes promotes the reaction [saikogenin A analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes promotes the reaction [saikogenin A inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes promotes the reaction [Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; isobavachalcone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; kansuinin A inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; kansuinin B inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; mesaconitine inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; rhein metabolite inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; rhein promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikogenin A analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikogenin A inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikogenin F inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikosaponin D analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikosaponin D inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; tanshinone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; toosendanin inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid] ABCB11 protein results in increased abundance of Taurodeoxycholic Acid [Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid |
CTD |
PMID:14570929 PMID:20147439 PMID:35101544 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Taurodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16101123 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases secretion |
ISO |
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurodeoxycholic Acid] AHR gene mutant form results in increased secretion of Taurodeoxycholic Acid |
CTD |
PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Taurodeoxycholic Acid results in increased activity of CASP3 protein ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:12773247 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO |
Taurodeoxycholic Acid results in increased activity of CASP9 protein ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein] |
CTD |
PMID:12773247 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
increases response to substance increases activity |
ISO |
CHRM3 protein results in increased susceptibility to Taurodeoxycholic Acid Taurodeoxycholic Acid results in increased activity of CHRM3 protein |
CTD |
PMID:15964566 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases hydroxylation |
ISO |
CYP3A4 protein results in increased hydroxylation of Taurodeoxycholic Acid |
CTD |
PMID:36473578 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases activity decreases expression |
EXP |
Taurodeoxycholic Acid results in decreased activity of CYP7B1 protein Taurodeoxycholic Acid results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:12029625 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases abundance |
ISO |
Taurodeoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein] IL10 gene mutant form results in increased abundance of Taurodeoxycholic Acid |
CTD |
PMID:26706406 PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases activity |
ISO |
Taurodeoxycholic Acid results in increased activity of MAPK14 protein |
CTD |
PMID:14762791 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases activity |
ISO |
Taurodeoxycholic Acid results in increased activity of NR1H4 protein |
CTD |
PMID:17567710 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pnlip |
pancreatic lipase |
affects folding |
ISO |
Taurodeoxycholic Acid affects the folding of PNLIP protein |
CTD |
PMID:19346257 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects abundance |
ISO |
POR gene mutant form affects the abundance of Taurodeoxycholic Acid |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Stim1 |
stromal interaction molecule 1 |
multiple interactions affects localization |
EXP |
STIM1 protein promotes the reaction [Taurodeoxycholic Acid results in increased abundance of Calcium] Taurodeoxycholic Acid affects the localization of STIM1 protein |
CTD |
PMID:18342630 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases secretion |
ISO |
AHR gene mutant form results in increased secretion of taurohyodeoxycholic acid |
CTD |
PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
affects localization decreases activity multiple interactions |
EXP ISO |
Taurolithocholic Acid affects the localization of ABCB11 protein Taurolithocholic Acid results in decreased activity of ABCB11 protein Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Taurolithocholic Acid affects the localization of and affects the activity of ABCB11 protein |
CTD |
PMID:12865277 PMID:15763547 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects localization multiple interactions |
EXP |
Taurolithocholic Acid affects the localization of ABCC2 protein 3-chloroacetylindole inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; [Colchicine co-treated with JTE 013] inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; CYM-5520 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein; Wortmannin inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein] |
CTD |
PMID:31300867 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Taurolithocholic Acid results in increased phosphorylation of AKT1 protein JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31300867 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions affects binding |
ISO |
[Taurolithocholic Acid binds to and affects the activity of CHRM3 protein] which results in increased abundance of Inositol Phosphates; Taurolithocholic Acid binds to and affects the activity of CHRM3 protein Taurolithocholic Acid binds to CHRM3 protein |
CTD |
PMID:12379313 PMID:12464352 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases hydroxylation |
ISO |
CYP3A4 protein results in increased hydroxylation of Taurolithocholic Acid |
CTD |
PMID:36473578 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Taurolithocholic Acid results in increased expression of FOS mRNA ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA] |
CTD |
PMID:18164257 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases abundance |
ISO |
HSD11B1 gene mutant form results in increased abundance of Taurolithocholic Acid |
CTD |
PMID:25061560 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Taurolithocholic Acid results in increased expression of JUN mRNA ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of JUN mRNA] |
CTD |
PMID:18164257 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases abundance |
ISO |
POR gene mutant form results in increased abundance of Taurolithocholic Acid |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
increases activity multiple interactions |
EXP |
Taurolithocholic Acid results in increased activity of PRKACA protein JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein] |
CTD |
PMID:31300867 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
multiple interactions |
EXP |
S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31300867 |
|
NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574
|
|
G |
Smad3 |
SMAD family member 3 |
increases abundance |
ISO |
SMAD3 protein results in increased abundance of Taurolithocholic Acid |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases sulfation |
ISO |
SULT2A1 protein results in increased sulfation of Taurolithocholic Acid |
CTD |
PMID:36473578 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases response to substance |
EXP |
AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein] AGT protein results in decreased susceptibility to taurolithocholic acid 3-sulfate |
CTD |
PMID:23300732 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
EXP |
AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein] |
CTD |
PMID:23300732 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity |
ISO |
taurolithocholic acid 3-sulfate results in decreased activity of CFTR protein |
CTD |
PMID:15634668 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects binding |
ISO |
taurolithocholic acid 3-sulfate binds to CHRM1 protein |
CTD |
PMID:12464352 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO |
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA] |
CTD |
PMID:22517774 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA] |
CTD |
PMID:22517774 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
|
G |
A2m |
alpha-2-macroglobulin |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of A2M mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aadat |
aminoadipate aminotransferase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of AADAT mRNA |
CTD |
PMID:15885361 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Aatf |
apoptosis antagonizing transcription factor |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of AATF mRNA |
CTD |
PMID:15885361 |
|
NCBI chr10:69,299,029...69,392,207
Ensembl chr10:69,299,037...69,392,201
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression multiple interactions increases expression |
EXP ISO |
ursodoxicoltaurine results in decreased expression of ABCB11 mRNA [ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCB11 protein ursodoxicoltaurine results in increased expression of and results in increased activity of ABCB11 protein ursodoxicoltaurine results in increased expression of ABCB11 protein |
CTD |
PMID:11672435 PMID:12644037 PMID:15885361 PMID:36787806 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16101123 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression |
EXP ISO |
ursodoxicoltaurine results in increased expression of and results in increased activity of ABCC2 protein [ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC2 protein ursodoxicoltaurine results in increased expression of ABCC2 protein |
CTD |
PMID:11672435 PMID:12644037 PMID:36787806 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of ABCC3 protein |
CTD |
PMID:11672435 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ACLY mRNA |
CTD |
PMID:15885361 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ACSL1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Actn1 |
actinin, alpha 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ACTN1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ADH1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adk |
adenosine kinase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ADK mRNA |
CTD |
PMID:15885361 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions |
EXP |
ursodoxicoltaurine results in decreased expression of AGT mRNA ursodoxicoltaurine inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of FN1 protein]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein] |
CTD |
PMID:15885361 PMID:25398788 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases abundance increases secretion |
ISO |
AHR gene mutant form results in increased abundance of ursodoxicoltaurine AHR gene mutant form results in increased secretion of ursodoxicoltaurine |
CTD |
PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:12721362 PMID:25398788 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Amy2a3 |
amylase 2a3 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of AMY1A mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:201,317,916...201,326,487
Ensembl chr 2:201,317,920...201,326,532
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
affects expression decreases expression |
EXP |
ursodoxicoltaurine affects the expression of APAF1 mRNA; ursodoxicoltaurine affects the expression of APAF1 protein ursodoxicoltaurine results in decreased expression of APAF1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of APOA1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[ursodoxicoltaurine co-treated with Indomethacin] results in increased expression of APOB mRNA; [ursodoxicoltaurine co-treated with Tunicamycin] results in increased expression of APOB mRNA; ursodoxicoltaurine inhibits the reaction [Allopurinol results in decreased secretion of APOB protein]; ursodoxicoltaurine inhibits the reaction [Fluorouracil results in decreased expression of APOB mRNA]; ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in decreased secretion of APOB protein] |
CTD |
PMID:32535746 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of TRP53 protein] ursodoxicoltaurine affects the reaction [APP protein modified form affects the localization of NR3C2 protein]; ursodoxicoltaurine inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; ursodoxicoltaurine inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein] |
CTD |
PMID:16728529 PMID:16923170 PMID:18368144 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp8 |
aquaporin 8 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of AQP8 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ARG1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arl1 |
ADP-ribosylation factor like GTPase 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of ARL1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898
|
|
G |
As3mt |
arsenite methyltransferase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of AS3MT mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression multiple interactions |
ISO |
ursodoxicoltaurine results in decreased expression of ATF4 mRNA ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased expression of ATF4 protein] ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF4 mRNA] |
CTD |
PMID:24312631 PMID:28223344 PMID:35524978 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF6 mRNA] |
CTD |
PMID:20165829 PMID:28223344 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions increases phosphorylation |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in decreased activity of BAD protein]; ursodoxicoltaurine results in increased phosphorylation of and results in decreased activity of BAD protein ursodoxicoltaurine results in increased phosphorylation of and affects the localization of BAD protein; Wortmannin inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and affects the localization of BAD protein] ursodoxicoltaurine results in increased phosphorylation of BAD protein |
CTD |
PMID:12721362 PMID:15190125 PMID:17559149 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO EXP |
ursodoxicoltaurine affects the localization of and results in decreased susceptibility to BAX protein; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of BAX protein] ursodoxicoltaurine results in decreased expression of BAX protein ursodoxicoltaurine inhibits the reaction [3-nitropropionic acid affects the localization of BAX protein]; ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] ursodoxicoltaurine results in increased expression of BAX protein |
CTD |
PMID:11080188 PMID:12627974 PMID:12721362 PMID:15255934 PMID:16923170 PMID:17881359 PMID:35028790 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
ursodoxicoltaurine results in increased expression of BCL2 mRNA; ursodoxicoltaurine results in increased expression of BCL2 protein ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [shikonin inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein]] ursodoxicoltaurine inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein] ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:12721362 PMID:15255934 PMID:16923170 PMID:29751043 PMID:35028790 PMID:35524978 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:12721362 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
C4b |
complement C4B |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of C4B mRNA |
CTD |
PMID:15885361 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Calr |
calreticulin |
multiple interactions |
EXP |
ursodoxicoltaurine promotes the reaction [Cisplatin results in increased expression of CALR mRNA] |
CTD |
PMID:33631298 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Canx |
calnexin |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of CANX protein] |
CTD |
PMID:27588471 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased cleavage of CASP12 protein] ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased cleavage of CASP12 protein]; ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of CASP12 mRNA] |
CTD |
PMID:12198651 PMID:33631298 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein] |
CTD |
PMID:16923170 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases activity |
EXP ISO |
ursodoxicoltaurine inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; ursodoxicoltaurine inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Neurotoxins results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein] ursodoxicoltaurine inhibits the reaction [1-Naphthylisothiocyanate results in increased cleavage of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of CASP3 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of CASP3 protein] ursodoxicoltaurine inhibits the reaction [Cyclosporine results in increased cleavage of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein] ursodoxicoltaurine results in decreased activity of CASP3 protein |
CTD |
PMID:12198651 PMID:12773247 PMID:15190125 PMID:15222754 PMID:17436368 PMID:17559149 PMID:18368144 PMID:29751043 PMID:35033536 PMID:35524978 PMID:36787806 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP4 protein] |
CTD |
PMID:17559149 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein] |
CTD |
PMID:16923170 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased activity of CASP7 protein]; ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased activity of CASP7 protein] |
CTD |
PMID:12198651 PMID:17559149 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased activity of CASP9 protein; ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein] |
CTD |
PMID:12773247 PMID:14976352 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CCN2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
EXP |
ursodoxicoltaurine inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein] ursodoxicoltaurine results in decreased expression of CCND1 mRNA; ursodoxicoltaurine results in decreased expression of CCND1 protein |
CTD |
PMID:15885361 PMID:17431217 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh17 |
cadherin 17 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CDH17 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CDH2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of CEBPD mRNA |
CTD |
PMID:15885361 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Xylitol results in increased expression of CHAC1 protein] |
CTD |
PMID:32275922 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CITED2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CPS1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein]; calphostin C inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein]; KN 62 inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein]; ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein |
CTD |
PMID:15861431 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in decreased activity of CS protein]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in decreased expression of CS mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CSAD mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CTH mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP2A2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP2B3 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c12 |
cytochrome P450, family 2, subfamily c, polypeptide 12 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP2C12 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP2F4 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases hydroxylation |
ISO |
CYP3A4 protein results in increased hydroxylation of ursodoxicoltaurine |
CTD |
PMID:36473578 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of CYP4F1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP7A1 protein] |
CTD |
PMID:36787806 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP ISO |
ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein] ursodoxicoltaurine inhibits the reaction [2,4-dichlorophenol results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of DDIT3 mRNA] ursodoxicoltaurine inhibits the reaction [Cyclosporine results in increased expression of and affects the localization of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [hydroquinone results in increased expression of and affects the localization of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein] |
CTD |
PMID:23544086 PMID:24053669 PMID:24802810 PMID:27853103 PMID:28223344 PMID:29027487 PMID:29751043 PMID:33631298 PMID:35033536 PMID:35524978 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of DPP4 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression decreases expression |
EXP |
ursodoxicoltaurine results in increased expression of E2F1 mRNA ursodoxicoltaurine results in decreased expression of E2F1 protein |
CTD |
PMID:15255934 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
ursodoxicoltaurine results in decreased expression of EDN1 protein |
CTD |
PMID:15556138 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]; ursodoxicoltaurine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein]; ursodoxicoltaurine promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:26803847 PMID:35028790 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein] ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]; ursodoxicoltaurine promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]] |
CTD |
PMID:24802810 PMID:35028790 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of ENPP1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
|
|
G |
Ergic3 |
ERGIC and golgi 3 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Tunicamycin results in decreased expression of ERGIC3 protein] |
CTD |
PMID:27588471 |
|
NCBI chr 3:144,525,059...144,534,813
Ensembl chr 3:144,525,092...144,534,813
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:29031535 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esrrg |
estrogen-related receptor gamma |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Dronabinol results in increased expression of ESRRG mRNA] |
CTD |
PMID:31054322 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
ursodoxicoltaurine results in decreased expression of FABP4 mRNA |
CTD |
PMID:24312631 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of FADS1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads3 |
fatty acid desaturase 3 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of FADS3 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of FAH mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of FAS mRNA |
CTD |
PMID:14623915 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Dronabinol results in increased expression of FLT1 mRNA] |
CTD |
PMID:31054322 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of FMO3 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression multiple interactions |
EXP |
ursodoxicoltaurine results in decreased expression of FN1 mRNA ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of FN1 protein] |
CTD |
PMID:15885361 PMID:25398788 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA] |
CTD |
PMID:18164257 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol results in decreased acetylation of FOXO1 protein] |
CTD |
PMID:23544086 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Ftcd |
formimidoyltransferase cyclodeaminase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of FTCD mRNA |
CTD |
PMID:15885361 |
|
NCBI chr20:12,055,203...12,068,717
Ensembl chr20:12,055,208...12,068,735
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of G6PC1 mRNA]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of G6PC1 protein] |
CTD |
PMID:23544086 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of GAMT mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778
|
|
G |
Gckr |
glucokinase regulator |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of GCKR mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 6:25,044,592...25,075,834
Ensembl chr 6:25,045,100...25,075,654
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of GLUD1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
decreases expression |
ISO |
ursodoxicoltaurine results in decreased expression of GPBAR1 mRNA |
CTD |
PMID:24312631 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
ursodoxicoltaurine affects the reaction [NR1H4 protein affects the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]]; ursodoxicoltaurine promotes the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein] |
CTD |
PMID:36787806 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of GSTA5 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of GSTM3 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of GSTP1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Haao |
3-hydroxyanthranilate 3,4-dioxygenase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of HAAO mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of HADH mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of HBP1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hdac3 |
histone deacetylase 3 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]] |
CTD |
PMID:23544086 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac4 |
histone deacetylase 4 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of HDAC4 protein] |
CTD |
PMID:23544086 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of HDAC5 protein] |
CTD |
PMID:23544086 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hdac7 |
histone deacetylase 7 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of HDAC7 protein] |
CTD |
PMID:23544086 |
|
NCBI chr 7:128,923,918...128,961,926
Ensembl chr 7:128,923,920...128,962,072
|
|
G |
Hdhd2 |
haloacid dehalogenase-like hydrolase domain containing 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of HDHD2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr18:70,488,315...70,526,471
Ensembl chr18:70,474,926...70,526,470
|
|
G |
Hpn |
hepsin |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of HPN mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
|
|
G |
Hrg |
histidine-rich glycoprotein |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of HRG mRNA |
CTD |
PMID:15885361 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases expression multiple interactions decreases abundance |
EXP ISO |
ursodoxicoltaurine results in decreased expression of HSD11B1 mRNA ursodoxicoltaurine inhibits the reaction [Nicotine results in increased expression of HSD11B1 mRNA] HSD11B1 gene mutant form results in decreased abundance of ursodoxicoltaurine |
CTD |
PMID:15885361 PMID:25061560 PMID:26803847 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd17b6 |
hydroxysteroid (17-beta) dehydrogenase 6 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of HSD17B6 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP ISO |
ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein] ursodoxicoltaurine inhibits the reaction [2,4-dichlorophenol results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [2,4-dichlorophenol results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of HSPA5 mRNA] ursodoxicoltaurine results in increased expression of HSPA5 protein ursodoxicoltaurine inhibits the reaction [Amiodarone results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Amiodarone results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Xylitol results in increased expression of HSPA5 protein] |
CTD |
PMID:12198651 PMID:20165829 PMID:24802810 PMID:25160872 PMID:25295624 PMID:27853103 PMID:28223344 PMID:29027487 PMID:29751043 PMID:32275922 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ifna1 |
interferon, alpha 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 mRNA]; ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 protein] |
CTD |
PMID:15885359 |
|
NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of IGF1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il10 |
interleukin 10 |
increases abundance |
ISO |
IL10 gene mutant form results in increased abundance of ursodoxicoltaurine |
CTD |
PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein] |
CTD |
PMID:29031535 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein] |
CTD |
PMID:29031535 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ITPR1 mRNA]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ITPR1 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ITPR2 mRNA]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ITPR2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of JUN mRNA] |
CTD |
PMID:18164257 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kng2 |
kininogen 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of KNG2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Acetaminophen results in decreased activity of LDHA protein] |
CTD |
PMID:38042273 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lgals5 |
galectin 5 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of LGALS5 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr10:63,853,949...63,857,198
Ensembl chr10:63,853,935...63,857,153
|
|
G |
Lgals9 |
galectin 9 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of LGALS9 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045
|
|
G |
Limk2 |
LIM domain kinase 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of LIMK2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007
|
|
G |
Lmbrd1 |
LMBR1 domain containing 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of LMBRD1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 9:27,096,387...27,178,095
Ensembl chr 9:27,096,297...27,178,090
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of LOX mRNA |
CTD |
PMID:15885361 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Maob |
monoamine oxidase B |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of MAOB mRNA |
CTD |
PMID:15885361 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein] |
CTD |
PMID:18368144 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Masp2 |
MBL associated serine protease 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of MASP2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 5:159,035,892...159,049,561
Ensembl chr 5:159,035,911...159,049,580
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of MDM2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] |
CTD |
PMID:20165829 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of MFN2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:24802810 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of MX2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342
|
|
G |
Nfia |
nuclear factor I/A |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of NFIA mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of NFKBIA protein |
CTD |
PMID:12721362 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein] |
CTD |
PMID:29031535 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of NOS2 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of NOS2 protein] |
CTD |
PMID:29751043 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR0B2 protein] |
CTD |
PMID:36787806 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of NR1D2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of NR1H4 protein; ursodoxicoltaurine affects the reaction [NR1H4 protein affects the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]] |
CTD |
PMID:36787806 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 mRNA]; ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 protein] [ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C1 protein |
CTD |
PMID:15222754 PMID:15885359 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
affects binding increases expression increases localization multiple interactions |
EXP |
ursodoxicoltaurine binds to NR3C2 protein ursodoxicoltaurine results in increased expression of NR3C2 mRNA ursodoxicoltaurine results in increased localization of NR3C2 protein [ursodoxicoltaurine binds to NR3C2 protein] which affects the localization of NR3C2 protein; [ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C2 protein; ursodoxicoltaurine affects the reaction [APP protein modified form affects the localization of NR3C2 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 mRNA]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 protein] |
CTD |
PMID:15222754 PMID:16728529 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nup62 |
nucleoporin 62 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of NUP62 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:95,298,995...95,314,902
Ensembl chr 1:95,295,526...95,315,174
|
|
G |
Os9 |
OS9, endoplasmic reticulum lectin |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of OS9 mRNA] |
CTD |
PMID:33631298 |
|
NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745
|
|
G |
Otc |
ornithine transcarbamylase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of OTC mRNA |
CTD |
PMID:15885361 |
|
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G |
Pacs2 |
phosphofurin acidic cluster sorting protein 2 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of PACS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:132,096,992...132,156,702
Ensembl chr 6:132,096,901...132,154,583
|
|
G |
Pah |
phenylalanine hydroxylase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of PAH mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased cleavage of PARP1 protein |
CTD |
PMID:14976352 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased activity of PC protein] |
CTD |
PMID:28223344 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol results in decreased acetylation of PCK1 protein]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of PCK1 mRNA]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of PCK1 protein] |
CTD |
PMID:23544086 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdlim1 |
PDZ and LIM domain 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of PDLIM1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of PECR mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of PHYH mRNA |
CTD |
PMID:15885361 |
|
NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects abundance |
ISO |
POR gene mutant form affects the abundance of ursodoxicoltaurine |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases abundance |
ISO |
PPARA gene mutant form results in decreased abundance of ursodoxicoltaurine |
CTD |
PMID:29175453 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO EXP |
ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] |
CTD |
PMID:20165829 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein] |
CTD |
PMID:16923170 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of RB1 protein |
CTD |
PMID:15255934 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rnf138 |
ring finger protein 138 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of RNF138 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr18:12,291,557...12,315,931
Ensembl chr18:12,291,590...12,315,930
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of S100A6 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Scarb2 |
scavenger receptor class B, member 2 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of SCARB2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr14:15,558,271...15,609,813
Ensembl chr14:15,558,236...15,609,813
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SCD1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scp2 |
sterol carrier protein 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SCP2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287
|
|
G |
Serp1 |
stress-associated endoplasmic reticulum protein 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of SERP1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:142,757,254...142,761,243
Ensembl chr 2:142,757,270...142,761,116
|
|
G |
Serpina1 |
serpin family A member 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased activity of CASP7 protein]; ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP4 protein] |
CTD |
PMID:17559149 |
|
NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
|
|
G |
Serpind1 |
serpin family D member 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SERPIND1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519
|
|
G |
Sh3bp5 |
SH3-domain binding protein 5 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SH3BP5 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr16:6,583,462...6,678,344
Ensembl chr16:6,583,465...6,698,975
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of SIRT2 protein] |
CTD |
PMID:23544086 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
[1-Naphthylisothiocyanate co-treated with ursodoxicoltaurine] results in decreased expression of SLC10A1 protein |
CTD |
PMID:36787806 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of SLC10A2 protein |
CTD |
PMID:11672435 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SLC22A8 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc26a1 |
solute carrier family 26 member 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SLC26A1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr14:1,040,565...1,045,851
Ensembl chr14:1,040,243...1,045,849
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP ISO |
ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] |
CTD |
PMID:20165829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc37a4 |
solute carrier family 37 member 4 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SLC37A4 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301
|
|
G |
Slc38a3 |
solute carrier family 38, member 3 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SLC38A3 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 8:108,323,889...108,339,959
Ensembl chr 8:108,323,894...108,339,988
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
ISO |
[1-Naphthylisothiocyanate co-treated with ursodoxicoltaurine] results in increased expression of SLC4A2 protein |
CTD |
PMID:36787806 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of SLC51B protein |
CTD |
PMID:36787806 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of SLC6A9 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Smad3 |
SMAD family member 3 |
increases abundance |
ISO |
SMAD3 protein results in increased abundance of ursodoxicoltaurine |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
3-Hydroxybutyric Acid promotes the reaction [ursodoxicoltaurine inhibits the reaction [SNCA protein results in increased susceptibility to Rotenone]]; ursodoxicoltaurine inhibits the reaction [SNCA protein results in increased susceptibility to Rotenone] |
CTD |
PMID:16239214 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]] |
CTD |
PMID:25398788 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stmn1 |
stathmin 1 |
increases expression |
EXP |
ursodoxicoltaurine results in increased expression of STMN1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SULT1A1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of SULT1B1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Tagln |
transgelin |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of TAGLN mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of TDO2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C1 protein; [ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C2 protein; ursodoxicoltaurine inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 mRNA]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein] |
CTD |
PMID:15222754 PMID:25398788 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbi |
transforming growth factor, beta induced |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of TGFBI mRNA |
CTD |
PMID:15885361 |
|
NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240
|
|
G |
Tgm2 |
transglutaminase 2 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of TGM2 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of THRSP mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tm4sf4 |
transmembrane 4 L six family member 4 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of TM4SF4 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr 2:141,570,321...141,621,263
Ensembl chr 2:141,481,902...141,621,200
|
|
G |
Tmem37 |
transmembrane protein 37 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of TMEM37 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr13:31,184,322...31,191,477
Ensembl chr13:31,171,355...31,191,077
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions affects response to substance |
EXP ISO |
ursodoxicoltaurine inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]; ursodoxicoltaurine results in increased expression of and results in increased stability of TP53 protein ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of TRP53 protein] TP53 protein affects the susceptibility to ursodoxicoltaurine |
CTD |
PMID:15255934 PMID:16923170 PMID:17431217 PMID:17881359 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Uggt1 |
UDP-glucose glycoprotein glucosyltransferase 1 |
multiple interactions |
EXP |
ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of UGGT1 mRNA]; ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of UGGT1 protein] |
CTD |
PMID:33631298 |
|
NCBI chr 9:38,355,229...38,468,473
Ensembl chr 9:38,359,089...38,468,467
|
|
G |
Ugt2b |
UDP glycosyltransferase 2 family, polypeptide B |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of UGT2B mRNA |
CTD |
PMID:15885361 |
|
NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776
|
|
G |
Upb1 |
beta-ureidopropionase 1 |
decreases expression |
EXP |
ursodoxicoltaurine results in decreased expression of UPB1 mRNA |
CTD |
PMID:15885361 |
|
NCBI chr20:13,217,252...13,243,590
Ensembl chr20:13,217,258...13,243,590
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of VDAC1 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
ursodoxicoltaurine inhibits the reaction [Dronabinol results in increased expression of VEGFA mRNA] |
CTD |
PMID:31054322 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
EXP ISO |
ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased expression of XBP1 protein] |
CTD |
PMID:20165829 PMID:35524978 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|